Sanofi (SNY) EBIT (QoQ) (2009 - 2026)
Analysis
Sanofi (SNY) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.99% |
| Mar 31, 2026 | 144.47% |
| Dec 31, 2025 | -164.70% |
| Sep 30, 2025 | 417.23% |
| Jun 30, 2025 | -30.58% |
| Mar 31, 2025 | 292.54% |
| Dec 31, 2024 | -84.25% |
| Sep 30, 2024 | 135.58% |
| Jun 30, 2024 | 22.87% |
| Mar 31, 2024 | -82.07% |
| Dec 31, 2023 | 114.24% |
| Sep 30, 2023 | 72.67% |
| Jun 30, 2023 | -23.43% |
| Mar 31, 2023 | -60.46% |
| Dec 31, 2022 | 143.42% |
| Sep 30, 2022 | 79.74% |
| Jun 30, 2022 | -43.20% |
| Mar 31, 2022 | -64.52% |
| Dec 31, 2021 | 112.06% |
| Sep 30, 2021 | 92.92% |